Abstract: An antibody that binds to a filovirus glycoprotein generally includes include a complementarity determining region (CDR) of any one of SEQ ID NO:27-36 or a combination of such CDRs. The antibody may be used in to detect filovirus in a biological sample obtained from a subject. The antibody also may be formulated into a pharmaceutical composition for administering to a subject having, or at risk of having, a filovirus infection.

Abstract: A composition for treating pain includes an antibody or antibody fragment that specifically binds to a receptor involved in pain. In some embodiments, the receptor is a P2X family receptor such as, for example, P2X4. In some embodiments, the antibody includes a detectable marker. In some of these embodiments, the detectable marker includes a fluorescent tag. The composition may be used to treat acute or chronic pain in a subject. Generally, the methods includes administering to the subject a composition that includes an antibody or antibody fragment that specifically binds to a receptor involved in pain. The non-opioid pain relief composition can reverse pain related mechanical, cold, anxiety-like, and depression-like behaviors in neuropathic pain and chemotoxic nerve injury models.

Abstract: A pharmaceutical composition generally includes a therapeutic antibody, or fragment thereof, and a pharmaceutically acceptable carrier. The therapeutic antibody specifically binds to a target peptide that mediates pain in a subject. The composition may be administered to a subject experiencing pain to at least partially alleviate the pain.